ADC Control Human IgG1-Deruxtecan (DAR 8)
The ADC Control Human IgG1-Deruxtecan (DAR 8) is a humanized monoclonal antibody conjugated with Deruxtecan, a potent topoisomerase I inhibitor. Researchers use this conjugate as an isotype control in antibody-drug conjugate (ADC) studies to assess nonspecific effects in experimental setups.
Key Features:
- Isotype Control: Utilizes a human IgG1 antibody that does not target specific antigens, ensuring observed effects are due to the drug conjugate and not antibody specificity.
- Drug-Linker Conjugate: Combines Deruxtecan with a cleavable linker for effective delivery of the cytotoxic agent.
- Drug-to-Antibody Ratio (DAR): Features a DAR of 8, meaning an average of 8 drug molecules are attached to each antibody.
Applications:
- Control in ADC Studies: Acts as a negative control to help distinguish between specific and nonspecific effects in ADC experiments.
- Mechanistic Research: Helps study the pharmacokinetics and pharmacodynamics of ADCs.
- Method Development: Supports the development and validation of analytical methods for ADC characterization.
Handling and Storage:
- Storage: Store at -20°C, protected from light and moisture.
- Handling: Use standard laboratory precautions when handling this reagent.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.